Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM313 in systemic lupus erythematosus (Ib/IIa)
CTR20221639Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cm313 in systemic lupus erythematosus (SLE), sponsored by Keymed Biosciences. Started Jul 2022; status: completed.
02
Drugs
cm313
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20221639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221639.